Loading [Contrib]/a11y/accessibility-menu.js
Review

Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases

  • Received: 03 May 2017 Accepted: 09 October 2017 Published: 19 October 2017
  • Immune system dysfunction is one of the key features in onset and development of cancer and autoimmunity. Cytotoxic T-lymphocyte-antigen-4 (CTLA-4), as a leader immune checkpoint plays a crucial effects in the regulation of immune suppression and tolerance. In this review, role of CTLA-4 and its three important polymorphisms (SNP), CTLA-4 +49A/G, CTLA-4 CT60 A/G and CTLA-4 −318C/T in development of cancer and autoimmune diseases have been discussed. The evidences revealed that CTLA-4 +49A/G, A allele increases the risk of cervical cancer and CTLA-4 +49A/G G allele decreases the risk of breast cancer in Asian population. The presence of G allele of CTLA-4 +49A/G SNP is strongly correlates with increased risk of Graves and systemic lupus erythematous (SLE), in Asian and European population. G allele of CTLA-4 +49A/G SNP may be a risk factor for rheumatoid arthritis susceptibility (RA). Evidence suggests that the presence of CTLA-4 +49 G allele reduces the inhibitory function of CTLA-4 on T cells. Therefore, it is logical to propose that G allele of CTLA-4 +49 A/G increases the immune system activity and decreases the risk of cancer. The evidence on the effect of CTLA-4 CT60 A/G SNP on the risk of cancer development and autoimmune disorders is inconclusive. No association was found between the CTLA-4 −318C/T polymorphism with autoimmune diseases.

    Citation: Maryam Tanhapour, Asad Vaisi-Raygani, Mozafar Khazaei, Zohreh Rahimi, Tayebeh Pourmotabbed. Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases[J]. AIMS Medical Science, 2017, 4(4): 395-412. doi: 10.3934/medsci.2017.4.395

    Related Papers:

    [1] Rena Rahimova . Relationship between CTLA4, TNF-α and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis. AIMS Medical Science, 2023, 10(1): 14-23. doi: 10.3934/medsci.2023002
    [2] Michiro Muraki . Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review. AIMS Medical Science, 2022, 9(2): 98-267. doi: 10.3934/medsci.2022009
    [3] Claudia Chaufan, Laurie Manwell, Camila Heredia, Jennifer McDonald . COVID-19 vaccines and autoimmune disorders: A scoping review protocol. AIMS Medical Science, 2023, 10(4): 318-328. doi: 10.3934/medsci.2023025
    [4] Alessandro P. Delitala . Autoimmunity in latent autoimmune diabetes in adults. AIMS Medical Science, 2019, 6(2): 132-139. doi: 10.3934/medsci.2019.2.132
    [5] Nádia C. M. Okuyama, Fernando Cezar dos Santos, Kleber Paiva Trugilo, Karen Brajão de Oliveira . Involvement of CXCL12 Pathway in HPV-related Diseases. AIMS Medical Science, 2016, 3(4): 417-440. doi: 10.3934/medsci.2016.4.417
    [6] Hamidreza Mohammadi, Mohammad Shokrzadeh, Majid Darvish, Ayat Dashti, Majid Jafari Sabet, Saeed Kavoosian, Ramin Ataee . Effect of curcumin nano-micelle on of 1,2, dimethylhydrazine-induced rat colon carcinogenesis in comparison with 5FU. AIMS Medical Science, 2020, 7(3): 223-233. doi: 10.3934/medsci.2020013
    [7] Sherven Sharma, Pournima Kadam, Ram P Singh, Michael Davoodi, Maie St John, Jay M Lee . CCL21-DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer. AIMS Medical Science, 2021, 8(4): 269-275. doi: 10.3934/medsci.2021022
    [8] Wenping Lin, Kai Dai, Luokun Xie . Recent Advances in αβ T Cell Biology: Wnt Signaling, Notch Signaling, Hedgehog Signaling and Their Translational Perspective. AIMS Medical Science, 2016, 3(4): 312-328. doi: 10.3934/medsci.2016.4.312
    [9] Salma M. AlDallal . Quick glance at Fanconi anemia and BRCA2/FANCD1. AIMS Medical Science, 2019, 6(4): 326-336. doi: 10.3934/medsci.2019.4.326
    [10] Mansour Shakiba, Mohammad Hashemi, Zahra Rahbari, Salah Mahdar, Hiva Danesh, Fatemeh Bizhani, Gholamreza Bahari . Lack of Association between Human µ-Opioid Receptor (OPRM1) Gene Polymorphisms and Heroin Addiction in A Sample of Southeast Iranian Population. AIMS Medical Science, 2017, 4(2): 233-240. doi: 10.3934/medsci.2017.2.233
  • Immune system dysfunction is one of the key features in onset and development of cancer and autoimmunity. Cytotoxic T-lymphocyte-antigen-4 (CTLA-4), as a leader immune checkpoint plays a crucial effects in the regulation of immune suppression and tolerance. In this review, role of CTLA-4 and its three important polymorphisms (SNP), CTLA-4 +49A/G, CTLA-4 CT60 A/G and CTLA-4 −318C/T in development of cancer and autoimmune diseases have been discussed. The evidences revealed that CTLA-4 +49A/G, A allele increases the risk of cervical cancer and CTLA-4 +49A/G G allele decreases the risk of breast cancer in Asian population. The presence of G allele of CTLA-4 +49A/G SNP is strongly correlates with increased risk of Graves and systemic lupus erythematous (SLE), in Asian and European population. G allele of CTLA-4 +49A/G SNP may be a risk factor for rheumatoid arthritis susceptibility (RA). Evidence suggests that the presence of CTLA-4 +49 G allele reduces the inhibitory function of CTLA-4 on T cells. Therefore, it is logical to propose that G allele of CTLA-4 +49 A/G increases the immune system activity and decreases the risk of cancer. The evidence on the effect of CTLA-4 CT60 A/G SNP on the risk of cancer development and autoimmune disorders is inconclusive. No association was found between the CTLA-4 −318C/T polymorphism with autoimmune diseases.


    1. Introduction

    Immune system dysfunction is one of the key features in onset and development of cancer and autoimmunity [1]. One reason for the development of malignancies is failure of T lymphocytes to recognize tumor-specific antigens. Presentation of antigen to T cell receptor (TCR) by major histocompatibility complex (MHC) proteins is a part of T cells mechanism to eliminate foreign antigen [2,3,4]. Antigen presentation to T cells alone however, is not enough to achieve effective immunogenic cell death in emerging or progressing malignancies [2]. Complex protein-protein interactions contribute to T cell activation and lead to stimulatory and/or inhibitory signals production, necessary for normal function of the immune system [5].

    Interaction of CD28 (Cluster of Differentiation 28) or inducible costimulator (ICOS) [6] receptors from T cell with CD 80 (B7-1) or CD86 (B7-2) ligands from antigen presenting cell (APC) activates T cell, leading to secretion of cytokines [7,8]. T cell activation and excessive expansion of activated T cells is inhibited by negative signals provided by immune checkpoints, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death 1 (PD-1) [9]. Both CD28 and CTLA-4 receptors bind to CD80 and CD86 with different affinity. CD28 is a highly expressed receptor but has low-affinity for CD80 and CD86 ligands, whereas CTLA-4 is a low abundance receptor with higher-affinity for the ligands [10,11]. CTLA-4 serves as a negative regulator when it is associated with Treg cells and present antigen to T cells when they are expressed by antigen presenting cells [12]. CD28, on the other hand, is constitutively expressed on both resting and activated conventional T cells [13]. The lack of balance between these two receptors leads to malignancy and loss of immune tolerance [14]. It has been shown that inhibition of CTLA-4 results in increased activation of the immune system. This finding has led to new immunotherapies for melanoma [15,16], non–small cell lung cancer, and other cancers [17,18,19,20,21]. Activation of immune system by anti–CTLA-4 monoclonal antibody therapy apparently has improved the melanoma outcomes for cancer patients [22]. Despite many findings (information) regarding mechanisms by which CTLA-4 regulates T cell response, several studies suggest that genetic factors are involved in susceptibility to autoimmune diseases and malignancy [23,24,25,26].

    In this mini-review, the mechanism by which CTLA-4 regulates T cell response and the effect of its gene mutations as associated with autoimmune and cancer susceptibility will be discussed.


    2. CTLA-4 Structure and Function

    CTLA-4 (Gene ID:1493, MIM number:123890) is a new member of the immunoglobulin superfamily known as insulin-dependent diabetes mellitus 12 (IDDM 12) [27] and cluster of differentiation 152 (CD152) [28]. It is mapped to chromosome 2q33 with a nucleotide size of about 6.2 kb and consists of four exons and 3 introns [29]. The CTLA-4 protein consists of a 37 amino acid leader peptide, an extracellular immunoglobulin (Ig) V like domain or the ligand-binding domain (116 amino acid), a hydrophobic transmembrane region (37 amino acid), and a cytoplasmic domain [30,31,32]. Chistiakov et al. reported that the 5' region of the gene contains a Kozak consensus sequence with the ATG initiation codon, an in-frame stop codon 26 bp upstream of this ATG and a TATA box 75 bp upstream of the stop codon. The 3' untranslated region (UTR) comprises a stretch of almost 30 AT repeats [33].

    Three different isoforms of this protein have been identified (1) the surface full-length CTLA-4 (flCTLA-4) protein consisting of 149 amino acids where all four exons have expressed, (2) soluble transmembrane deleted CTLA-4 mutant protein (sCTLA-4), and (3) CTLA-4 mutant protein lacking both extracellular and transmembrane domains [34,35,36].

    CTLA-4 is an intracellular protein that translocates to cell surface through recruitment of enzymes such as GTPase ADP ribosylation factor-1 and phospholipase D [6,17,37]. An association between low expression of the sCTLA-4 and susceptibility to autoimmune diseases, such as Type 1 diabetes has been reported [31,32,38]. Although the importance of CTLA-4 in maintaining immune homeostasis is unquestionable, the mechanism of CTLA-4 function is still unclear. We have summarized several different pathways which have been suggested previously [39].

    Both T cell-intrinsic and T-cell extrinsic mechanism have been proposed for CTLA-4 as summarized in Figures 1 and 2 [40]. Carreno and coworkers have predicted that in early stages of immune response which CD80 is expressed at low levels, negative signal generated via CTLA-4 is a primary mechanism for inhibition of T lymphocyte activation. Whereas both CTLA-4 negative signaling through CTLA-4 and CD80 sequestration would be effective during later stages of immune response when CD80 expression is increased by IFN-gamma stimulation [52,53].

    Figure 1. T-cell intrinsic function.
    (a). CTLA-4 via recruitment of phosphatases such as protein phosphatase 2A (PP2A) decreases the phosphorylation of essential mediators for TCR signaling cascade, including CD3ζ, a transmembrane adaptor signaling protein. Therefore CTLA-4 delivers inhibitory signals which may interfere with stimuli signals generated by T-cell surface receptors such as CD28 [41]. This interferes with stimulatory signals generated by T-cell surface receptors such as CD28. The inhibitory effect of CTLA-4 through alterations in lipid raft location has also been proposed (Figure 1a) [42]. (b). soluble CTLA-4 due to lack of extracellular domain cannot bind ligands, therefore any negative signal is ligand independent [43]. (c) CTAL-4 prevents stimulus signal produced by CD28 through high affinity competition for CD80 and CD86 ligands [44]. (d). CTLA-4 ligation either increases adhesion via lymphocyte function-associated antigen 1 (LFA1) from T cell with intercellular adhesion molecule 1 (ICAM1) from APC or decreases residence time on the APC. So the TCR-mediated 'stop' signal, which is essential for lymphocyte activation is suppressed [45]. APC: antigen presenting cell, TCR: T cell receptor, MHC: major histocompatibility complex, LFA 1: lymphocyte function-associated antigen 1, ICAM 1: intercellular adhesion molecule 1.
    Figure 2. T cell-extrinsic CTLA-4 function.
    (a). CTLA-4 suppresses T cell proliferation through induction of indoleamine 2, 3-dioxygenase (IDO) activity in APCs. It has been shown that IDO suppresses antigen-specific T cell proliferation and permits tumor cells to escape from immune rejection through tryptophan depletion [46,47,48]. (b). CTLA-4 signals stimulate the production of negative regulators of immune homeostasis such as transforming growth factor β (TGFβ) and interleukin-10 (IL-10) [49] at sites of cell–cell interaction [50]. (c). Soluble CTLA-4 splice variant can be secreted by T cells and its ligation with CD80 and CD86 ligands leads to reach out for CD28 ligation and prevents other T cells from receiving stimulatory signals. (d). Stimulatory capacity of APCs can be blocked by CTLA-4 expression on the surface of T cells. CTLA-4 expression can induce trans-endocytosis of CD80 and CD86 from the opposite cell and consequently it lowers the level of ligands on the surface of APCs [51]. TGFβ: Transforming growth factor-β.

    CD4+CD25+FoxP3+ regulatory T cells are pro-inflammatory effector and anti-inflammatory suppressor cells which have an important role in maintenance of tolerance to self in models of transplantation. Krummey et al. have reported that CTLA-4 negative signals after transplantation were required for FoxP3+ Treg suppression and long term graft survival. Moreover, CD28 blocking by reagent causes long-term survival of skin and cardiac allografts and the effect of CD28 blocking depends on signals generated by CTLA-4 [54]. The importance of anti-CTLA-4 therapy, vaccine, chemotherapy and radiation together in various malignancy treatment especially advanced melanoma have been suggested [55,56].


    3. CTLA-4 Polymorphism

    Seventeen single nucleotide polymorphism (SNP) at positions –1765, –1722, –1661, –1577, –658, –319, 49,6230,6249,7092,7482,7982,8173,10242,10717,12131 and 12310 of CTLA-4 gene has been identified [57,58]. However, the functional role of only a few of the SNPs and their association with susceptibility to diseases are well documented. CTLA-4 +49 A/G SNP in exon 1 leads to alanine to threonine substitution in leader sequence and affects the protein processing in the endoplasmic reticulum (ER), leading to lower effective glycosylation which plays an important role in protein membrane expression [36,59]. Two of the most important CTLA-4 gene variations are G/A nucleotide transition at position -1661 and T/C change at –1722 within the promoter region [60]. T/C change at position –1722 affects binding sites of transcription factors, whereas G/A transition at position –1661 may alter the potential response element for myocyte enhancer factor 2 (MEF2) [61,62]. GG genotype compared with AA at +6230 (CT60) position leads to less expression of sCTLA-4 versus full-length isoform by 50%.

    Individuals with AA genotype and high levels of sCTLA-4 were protected against risk of some autoimmune diseases. Moreover +6230 (CT60) AA Vs GG genotype was associated with increased Treg cells levels in peripheral blood. Also the higher promoter activity and the higher expression of membrane CTLA-4 were associated with allelic variant at –318 C/T position in promoter region [36].

    In this mini review, the role of CTLA-4 +49 A/G, CT60 A/G, and –318 C/T SNPs in malignancies (Table 1) and autoimmune diseases susceptibility (Table 2) will be discussed.

    Table 1. Odds ratio and distribution of cytotoxic T lymphocyte CTLA-4 +49A/G, CT60 A/G and –318 C/T genotypes and alleles in different cancer patients and control subjects.
    Reference Population Disease SNP Patient control P OR
    +49A/G
    Dai/2017 Asia Breast G allele 4544 4515 < 0.001 0.8
    Han/2016 Bone tumors A vs. G 1003 1162 < 0.001 1.36
    Jaiswal/2014 India Bladder genotypes 200 200 3.74
    Gao/2014 Asia Cancer* GG vs. AA 16358 19737 0.75
    Liu/2014 Cervical A allele 2835 2560 < 0.05 1.16
    Minhas/2014 India Breast G allele 250 250 0.7 0.9
    Qiu/2013 Cervical GG+AG vs AA NS 0.94
    Khaghanzade /2010 Iran Lung Genotype 127 124 NS NS
    Hu/2010 China Cervical AA vs GG 719 719 1.66
    Hu/2010 China HCC AA vs GG 864 864 1.43
    Saenz Lopez /2009 Spain Renal AA 127 176
    Su/2007 Taiwan Cervical Genotype 144 378 NS NS
    Cheng/2006 gastric MALT lymphoma GG 62 250 0.04 4.1
    CT60A/G
    Jaiswal/2014 India Bladder Genotype 200 200 1.36
    Qiu/2013 Asia Cervical GG+AG vs. AA 0.75
    Bharti/2012 India Oral AA 130 180 3.0
    Erfani/2012 Iran Head & neck AA 80 85 0.004 0.34
    Khaghanzadeh/2010 Iran Lung Genotype 127 124 NS NS
    Saenz Lopez /2009 Renal AA 127 176 < 0.05
    Perez/2009 Spain AML relapse AA 143 0.004 2.64
    Su/2007 Taiwan Cervical genotypes 144 378 NS NS
    Cheng/2006 Taiwan gastric MALT lymphoma genotypes 62 250 NS NS
    –318C/T
    Lu/2016 Asian malignant tumor TT+TC vs.CC 3539 4690 < 0.05 1.28
    Han/2016 China bone tumors C vs. T 1003 1162 NS NS
    Jaiswal/2014 India Bladder Genotype 200 200 NS NS
    Liu/2014 Cervical C allele 2835 2560 < 0.05 0.79
    Qiu/2013 Asia Cervical TC vs. CC 2.02
    Rahimifar/2010 Iran Cervical CC 55 110 0.021
    Khaghanzadeh/2010 Iran Lung genotypes 127 124 NS NS
    Su/2007 Taiwan Cervical Genotype 144 378 0.03 1.99
    Cheng/2006 Taiwan gastric MALT lymphoma Genotypes 62 250 0.02 0.3
    AML: acute myeloid leukemia, NS: no significant, gastric MALT lymphoma: gastric mucosa-associated lymphoid tissue (MALT) lymphoma, HCC: hepatocellular carcinoma, Cancer: cervical cancer, breast cancer, lung cancer, HCC.
     | Show Table
    DownLoad: CSV
    Table 2. Odds ratio and distribution of cytotoxic T lymphocyte CTLA-4 +49A/G, CT60 A/G and –318 C/T genotypes and alleles in different autoimmune patients and control subjects.
    Reference Population Disease SNP Patient control P OR
    +49A/G
    Narooie/2017 Iran Hashimoto's thyroiditis Genotypes 82 104 NS NS
    Ting/2016 China Graves' G allele 289 158 0.001 1.5
    Sameem/2015 Pakistani RA GG 100 100 3.018
    Li/2014* Asia, Caucasian & Africa RA GG vs. AA 9805 10691 < 0.05 1.13
    Du/2014* Europe Graves' G allele 0.001 1.14
    Devaraju/2014 India SLE AG & GG 300 460 0.0001 2.29
    Liu/2014* Americas, Europe & Asia MS 12916 15455 NS NS
    Liu J/2013* Asia & Europe SLE Genotypes 1753 2279 NS NS
    Du L/2013* China Graves' GG+GA 2.57
    Zhai/2013* Asia SLE GG+GA 0.04 0.85
    Li/2012* Asia & Europe RA GG+AG vs. AA 1.18
    Si X/2012* Asia Graves' Genotypes 8288 9372 < 0.001 1.6
    Farra/2012 Lebanon thyroid Genotypes 128 186 NS NS
    Chang/2012* Asia SLE GG vs AA 1806 2490 1.53
    Paula/2011 Spain Graves' G allele 100 50 0.01 1.9
    Kimkong/2011 Thailand Graves' & SLE G allele 283 153 NS NS
    Chua/2010 Malaysia SLE Genotypes 130 130 NS NS
    Bicek/2009 AITD GG 0.04
    Khalilzadeh/2009 Iran Graves' GG 105 103 0.005 6.000
    Chong/2008 China Graves' GG 177 151 0.005
    Balbi/2007 Italy SSc G allele 43 93 0.07
    Greve/2007 Germany, Hungary & Poland MS Genotypes NS NS
    Han/2006* China Graves' Genotypes NS NS
    Vaidya/2002 England RA G allele 123 349 0.02 1.35
    Tomoyose/2002 Japan HT G allele 143 199 0.03
    Ahmed/2001 Japan SLE G allele 0.003
    CT60A/G
    Ting/2016 China Graves' G allele 289 158 < 0.001 1.63
    Liu/2014* America, Europe, and Asia MS 12916 15455 NS NS
    Du L/2013* China Graves' AA+AG 0.64
    Li/2012* Asia & Europe RA A allele 0.86
    Kimkong/2011 Thailand Graves' GG 132 153 > 0.05 1.43
    Chua/2010 Malaysia SLE Genotypes 130 130 NS NS
    Karabon/2009 Poland MS G allele 230 380 0.04
    Bicek/2009 AITD AA and AG NS NS
    Chong/2008 China Graves' GG 177 151 0.07
    Greve/2007 Germany Hungary & Poland MS Genotypes NS NS
    Han/2006* China Graves' Genotypes NS NS
    Torres/2004 Spain SLE G allele 395 293 0.01 1.32
    318C/T
    Narooie/2017 Iran Hashimoto's thyroiditis Genotypes 82 104 NS NS
    Ting/2016 China Graves' Genotype 289 158 NS NS
    Liu/2014* America, Europe and Asia MS 12916 15455 NS NS
    Pastuszak/2013 Poland AITDs CT 49 69 < 0.05
    Du L/2013* China Graves' TT+TC 0.7
    Khalilzadeh/2009 Iran Graves' genotypes 105 103 NS NS
    Chong/2008 China Graves' genotypes 177 151 NS NS
    Balbi/2007 Italy SSc T allele 43 93 0.03
    Tomoyose/2002 Japan HT genotypes 143 199 NS NS
    Hudson/2002 SLE 130 200 NS NS
    Ahmed/2001 Japan SLE genotypes NS NS
    *meta-analysis, thyroid disease: autoimmune thyroid disease, Graves' disease and Hashimoto's thyroiditis, NS: no significant, SLE: systemic lupus erythematosus, Auto. D: Autoimmune disease, AITD: autoimmune thyroid disease, SSc: Systemic sclerosis, HT: Hashimoto's thyroiditis, MS: multiple sclerosis, RA: rheumatoid arthritis.
     | Show Table
    DownLoad: CSV

    3.1. CTLA-4+49 A/G SNP (rs231775)

    Studies demonstrated that CTLA-4 +49A/G is strongly associated with autoimmune diseases [63,64]. A significant association was found between the presence of CTLA-4 +49A/G, G allele and GG+GA genotypes with increased risk of Graves' disease (GD) in Chinese [65], Spanish [66], European [67] and Iranian populations [68]. However, a meta-analysis in Chinese population indicated that CTLA-4 +49A/G genotype does not correlate with Graves' disease [69]. Si et al [70] on the other hand, in a meta-analysis revealed that CTLA-4 +49A/G SNP is an important factor in increased risk of GD among Asian population.

    A considerable association between G allele of CTLA-4 +49A/G SNP and increased risk of SLE has been found in Japanese and South Indian SLE patients while, many studies failed to indicate such an association in Asian and European population [71,72,73,74,75,76,77]. Interestingly, the meta-analysis performed by Zhai et al. revealed the protective effect of CTLA-4 +49A/G, GG+GA genotype against development of SLE disease in Asian populations [78]. Therefore, the role of CTLA-4 +49A/G, G allele in SLE trigger or development is not clear and more studies are needed to clarify the significance of CTLA-4 +49A/G polymorphism in susceptibility to SLE in different populations. The role of CTLA-4 +49A/G polymorphism as a risk factor for autoimmune disease such as Hashimoto's thyroiditis, SLE, multiple sclerosis and systemic sclerosis in various populations studied in current paper from Americas, Europe, and Asia has not been approved [79,80,81,82].

    One meta-analysis and two separate case control studies revealed that G allele of CTLA-4 +49A/G is associated with increased risk of RA in Asian and European population [83,84,85]. The CTLA-4 +49A/G, G allele on the other hand may have a role in reducing the risk of cancer while, A allele of CTLA-4 +49A/G may increase the risk of cancer.

    In a meta-analysis by Dai et al. the protective role of CTLA-4 +49A/G, G allele against breast cancer among Asian has been shown [86]. Also, the role of CTLA-4 +49A/G SNP in cervical cancer development has been investigated in meta-analysis by Liu et al. They indicated that in Asian population the presence of A allele CTLA-4 +49A/G increased risk of cervical cancer by 1.16 fold [87]. Similarly, a 1.36 fold increased risk of bone tumor was found for patients carrying CTLA-4 +49A/G, A allele in meta-analysis by Han [88].

    These studies suggest that the presence of CTLA-4 +49 G allele reduces the inhibitory function of CTLA-4 on T cells. Therefore, it is logical to propose that G allele of CTLA-4 +49 A/G increases the immune system activity and decreases the risk of cancer. As the immune system alone is not enough to inhibit tumor growth, the CTLA-4 +49 G allele is not the only factor responsible for loss of immune tolerance and onset of autoimmune disorder. We suggest that G allele of CTLA-4 +49 A/G may exacerbate conditions in which the immune response against foreign antigen will increase. Consequently, in combination with other stimulus factors, which are effective in activation of autoimmune reaction this may lead to immune attack against body's cells.

    Association of the AA genotype of CTLA-4 +49A/G with increased risk of renal, bladder, cervical and hepatocellular carcinoma (HCC) has been shown in Spanish, Chinese, and Indian populations [89,90,91]. Cheng and coworkers have provided evidence in support of significant association between the GG genotype of CTLA-4 +49A/G gene with gastric mucosa-associated lymphoid tissue (MALT) lymphoma [92]. However, there is a lack of correlation between CTLA-4 +49 A/G SNP with increased susceptibility to cancer in various populations from Asia [93,94,95,96,97].


    3.2. CTLA-4 CT60A/G (rs3087243)

    This CTLA-4 SNP is located in 30 UTR region containing regulatory elements and can affect the mRNA stability, degradation, and nuclear transport reported by Bharti [98]. The role of CT60 A allele as a protective factor against autoimmune diseases and the CT60 G allele as a risk factor have been emphasized in several studies [99,100]. Studies performed in Chinese and Spanish population have demonstrated that G allele of CTLA-4 CT60A/G increased the risk of GD and SLE diseases [65,101].

    In spite of a case control study that indicated a significant association between increased risk of acute myeloid leukemia (AML) and CTLA-4 CT60A/G, AA genotype in Spanish population, Erfani et al. have shown that AA genotype as well as A allele may have protective roles against head and neck cancer in Iranian population [102,103]. In addition, there are studies indicating lack of association of CTLA-4 CT60A/G SNP with cancer and autoimmune diseases [9,74,97]. Thus, the role of the CT60A/G polymorphism in CTLA-4 protein function and in pathogenesis of malignancies and autoimmune disorders remains unclear.


    3.3. CTLA-318C/T (rs5742909)

    Meta-analysis study indicated that CTLA-4 –318C/T, TT+TC strongly increased the risk of malignant cancer in Asian population [97,104]. In two case control studies performed in Asian populations, the CTLA-4 –318 C/T genotypes were in correlation with a lower risk of developing gastric mucosa-associated lymphoid tissue (MALT) lymphoma and cervical cancer [87,92]. In addition, CTLA-4 –318C/T polymorphism does not correlate with autoimmune diseases [79,105,106,107]. Thus, with regard to increased inhibitory function of CTLA-4 as a result of T allele substitution at position –318, it can be suggested that CTLA-4 –318C/T SNP is responsible for optimal immunological response to foreign antigens and prevention of autoimmune diseases.


    4. Conclusion

    The CTLA-4 SNP at position +49 in gene (A allele) may increase its inhibitory function and decrease T cell activation, which leads to weakness in immune response against cancer cells. In addition, CTLA-4 +49A/G, G allele may decrease the risk of cancer but increases the risk of autoimmune disease. The involvement of CTLA-4 +49A/G, G allele in the susceptibility to GD, however, is unclear. The results obtained from this study concerning with CT60 A/G and –318 C/T polymorphisms effects in contributing of elucidation of CTLA-4 function were inconclusive.


    Conflict of Interest

    The authors declare that there is no conflict of interest to disclose.


    [1] Caspi RR (2008) Immunotherapy of autoimmunity and cancer: The penalty for success. Nat Rev Immunol 8: 970-976. doi: 10.1038/nri2438
    [2] Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by ctla-4 blockade. Science 271: 1734.
    [3] Janeway Jr CA, Travers P, Walport M, et al. (2001) The major histocompatibility complex and its functions. Immunobiology.
    [4] Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse t-cell repertoire. Nature 402: 255-262.
    [5] Chambers CA, Kuhns MS, Egen JG, et al. (2001) Ctla-4-mediated inhibition in regulation of t cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594. doi: 10.1146/annurev.immunol.19.1.565
    [6] Rudd CE, Taylor A, Schneider H (2009) Cd28 and ctla‐4 coreceptor expression and signal transduction. Immunol Rev 229: 12-26.
    [7] Rutkowski R, Moniuszko T, Stasiak-Barmuta A, et al. (2003) Cd80 and cd86 expression on lps-stimulated monocytes and the effect of cd80 and cd86 blockade on il-4 and ifn-gamma production in nanotopic bronchial asthma. Arch Immunol Ther Exp (Warsz) 51: 421-428.
    [8] Linsley PS, Clark EA, Ledbetter JA (1990) T-cell antigen cd28 mediates adhesion with b cells by interacting with activation antigen b7/bb-1. Proc Natl Acad Sci U S A 87: 5031-5035. doi: 10.1073/pnas.87.13.5031
    [9] Greenwald RJ, Freeman GJ, Sharpe AH (2005) The b7 family revisited. Annu Rev Immunol 23: 515-548. doi: 10.1146/annurev.immunol.23.021704.115611
    [10] Collins AV, Brodie DW, Gilbert RJ, et al. (2002) The interaction properties of costimulatory molecules revisited. Immunity 17: 201-210.
    [11] Sansom D (2000) Cd28, ctla‐4 and their ligands: Who does what and to whom? Immunology 101: 169-177.
    [12] Wang XB, Zheng CY, Giscombe R, et al. (2001) Regulation of surface and intracellular expression of ctla‐4 on human peripheral t cells. Scand J Immunol 54: 453-458. doi: 10.1046/j.1365-3083.2001.00985.x
    [13] Linsley PS, Greene J, Tan P, et al. (1992) Coexpression and functional cooperation of ctla-4 and cd28 on activated t lymphocytes. J Exp Med 176: 1595-1604. doi: 10.1084/jem.176.6.1595
    [14] Buc M (1996) Immunopathogenic mechanisms in autoimmune processes: Autoantigens. Bratisl Lek Listy 97: 187-195.
    [15] Ribas A, Camacho LH, Lopez-Berestein G, et al. (2005) Antitumor activity in melanoma and anti-self responses in a phase i trial with the anti-cytotoxic t lymphocyte–associated antigen 4 monoclonal antibody cp-675,206. J Clin Oncol 23: 8968-8977. doi: 10.1200/JCO.2005.01.109
    [16] Maker AV, Phan GQ, Attia P, et al. (2005) Tumor regression and autoimmunity in patients treated with cytotoxic t lymphocyte–associated antigen 4 blockade and interleukin 2: A phase i/ii study. Ann Surg Oncol 12: 1005-1016. doi: 10.1245/ASO.2005.03.536
    [17] Buchbinder EI, Desai A (2016) Ctla-4 and pd-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 39: 98. doi: 10.1097/COC.0000000000000239
    [18] Quezada SA, Peggs KS, Curran MA, et al. (2006) Ctla4 blockade and gm-csf combination immunotherapy alters the intratumor balance of effector and regulatory t cells. J Clin Invest 116: 1935-1945. doi: 10.1172/JCI27745
    [19] Phan GQ, Yang JC, Sherry RM, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100: 8372-8377.
    [20] Hodi FS, Mihm MC, Soiffer RJ, et al. (2003) Biologic activity of cytotoxic t lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100: 4712-4717. doi: 10.1073/pnas.0830997100
    [21] Ribas A, Glaspy JA, Lee Y, et al. (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27: 354-367. doi: 10.1097/00002371-200409000-00004
    [22] Wolchok JD, Saenger Y (2008) The mechanism of anti-ctla-4 activity and the negative regulation of t-cell activation. Oncologist 13: 2-9.
    [23] Cooper GS, Miller FW, Pandey JP (1999) The role of genetic factors in autoimmune disease: Implications for environmental research. Environ Health Perspect 107: 693. doi: 10.1289/ehp.99107s5693
    [24] Remmersl EF, Longmanl RE, Dul Y, et al. (1996) A genome scan localizes five non-mhc loci controlling. Nat Genet 14.
    [25] Gupta B, Hawkins RD (2015) Epigenomics of autoimmune diseases. Immunol Cell Biol 93: 271-276. doi: 10.1038/icb.2015.18
    [26] Maurano MT, Humbert R, Rynes E, et al. (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337: 1190-1195.
    [27] Kamel AM, Mira MF, Mossallam GI, et al. (2014) Lack of association of ctla-4 +49 a/g polymorphism with predisposition to type 1 diabetes in a cohort of egyptian families. Egypt J Med Hum Genet 15: 25-30. doi: 10.1016/j.ejmhg.2013.09.002
    [28] Steiner K, Moosig F, Csernok E, et al. (2001) Increased expression of ctla‐4 (cd152) by t and b lymphocytes in wegener's granulomatosis. Clin Exp Immunol 126: 143-150. doi: 10.1046/j.1365-2249.2001.01575.x
    [29] Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of ctla-4 function. Annu Rev Immunol 24: 65-97. doi: 10.1146/annurev.immunol.24.021605.090535
    [30] Prans E (2010) Allelic variants of ctla-4 gene as important markers of immune regulation in type 1 diabetes.
    [31] Pawlak E, Kochanowska IE, Frydecka I, et al. (2005) The soluble ctla-4 receptor: A new marker in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 53: 336.
    [32] Ueda H, Howson JM, Esposito L, et al. (2003) Association of the t-cell regulatory gene ctla4 with susceptibility to autoimmune disease. Nature 423: 506-511. doi: 10.1038/nature01621
    [33] Chistiakov D, Turakulov R (2003) Ctla-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 31: 21-36. doi: 10.1677/jme.0.0310021
    [34] Magistrelli G, Jeannin P, Herbault N, et al. (1999) A soluble form of ctla‐4 generated by alternative splicing is expressed by nonstimulated human t cells. Eur J Immunol 29: 3596-3602. doi: 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y
    [35] Jakubczik F, Jones K, Nichols J, et al. (2016) A snp in the immunoregulatory molecule ctla-4 controls mrna splicing in vivo but does not alter diabetes susceptibility in the nod mouse. Diabetes 65: 120-128.
    [36] Ghaderi A (2011) Ctla4 gene variants in autoimmunity and cancer: A comparative review. Iran J Immunol 8: 127.
    [37] Valk E, Rudd CE, Schneider H (2008) Ctla-4 trafficking and surface expression. Trends Immunol 29: 272-279. doi: 10.1016/j.it.2008.02.011
    [38] Gerold KD, Zheng P, Rainbow DB, et al. (2011) The soluble ctla-4 splice variant protects from type 1 diabetes and potentiates regulatory t-cell function. Diabetes 60: 1955-1963. doi: 10.2337/db11-0130
    [39] Rudd CE (2008) The reverse stop-signal model for ctla4 function. Nat Rev Immunol 8: 153-160. doi: 10.1038/nri2253
    [40] Walker LS, Sansom DM (2011) The emerging role of ctla4 as a cell-extrinsic regulator of t cell responses. Nat Rev Immunol 11: 852-863. doi: 10.1038/nri3108
    [41] Parry RV, Chemnitz JM, Frauwirth KA, et al. (2005) Ctla-4 and pd-1 receptors inhibit t-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543-9553. doi: 10.1128/MCB.25.21.9543-9553.2005
    [42] Chikuma S, Imboden JB, Bluestone JA (2003) Negative regulation of t cell receptor–lipid raft interaction by cytotoxic t lymphocyte–associated antigen 4. J Exp Med 197: 129-135. doi: 10.1084/jem.20021646
    [43] Choi JM, Ahn MH, Chae WJ, et al. (2006) Intranasal delivery of the cytoplasmic domain of ctla-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12: 574-579. doi: 10.1038/nm1385
    [44] Thompson CB, Allison JP (1997) The emerging role of ctla-4 as an immune attenuator. Immunity 7: 445-450.
    [45] Schneider H, Downey J, Smith A, et al. (2006) Reversal of the tcr stop signal by ctla-4. Science 313: 1972-1975. doi: 10.1126/science.1131078
    [46] Uyttenhove C, Pilotte L, Théate I, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat med 9: 1269-1274. doi: 10.1038/nm934
    [47] Hwang SL, Chung NP-y, Chan JK-y, et al. (2005) Indoleamine 2, 3-dioxygenase (ido) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell res 15: 167-175. doi: 10.1038/sj.cr.7290282
    [48] Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154. doi: 10.1172/JCI31178
    [49] Vignali DA, Collison LW, Workman CJ (2008) How regulatory t cells work. Nat Rev Immunol 8: 523-532. doi: 10.1038/nri2343
    [50] Gorelik L, Flavell RA (2000) Abrogation of tgfβ signaling in t cells leads to spontaneous t cell differentiation and autoimmune disease. Immunity 12: 171-181.
    [51] Qureshi OS, Zheng Y, Nakamura K, et al. (2011) Trans-endocytosis of cd80 and cd86: A molecular basis for the cell-extrinsic function of ctla-4. Science 332: 600-603. doi: 10.1126/science.1202947
    [52] Carreno BM, Bennett F, Chau TA, et al. (2000) Ctla-4 (cd152) can inhibit t cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165: 1352-1356. doi: 10.4049/jimmunol.165.3.1352
    [53] Sharpe AH, Freeman GJ (2002) The b7–cd28 superfamily. Nat Rev Immunol 2: 116-126. doi: 10.1038/nri727
    [54] Krummey SM, Ford ML (2014) Braking bad: Novel mechanisms of ctla‐4 inhibition of t cell responses. Am J Transplant 14: 2685-2690. doi: 10.1111/ajt.12938
    [55] Grosso JF, Jure-Kunkel MN (2013) Ctla-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun 13: 5.
    [56] Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570. doi: 10.1126/science.1203486
    [57] Palacios R, Comas D, Elorza J, et al. (2008) Genomic regulation of ctla4 and multiple sclerosis. J Neuroimmunol 203: 108-115. doi: 10.1016/j.jneuroim.2008.06.021
    [58] Ramirez SA, Lao O, Soldevila M, et al. (2005) Haplotype tagging efficiency in worldwide populations in ctla4 gene. Genes Immun 6: 646-657.
    [59] Zheng J, Yu X, Jiang L, et al. (2010) Association between the cytotoxic t-lymphocyte antigen 4 + 49g> a polymorphism and cancer risk: A meta-analysis. BMC cancer 10: 522. doi: 10.1186/1471-2407-10-522
    [60] Pérez-García A, De la Cámara R, Román-Gómez J, et al. (2007) Ctla-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from hla-identical sibling donors. Blood 110: 461-467. doi: 10.1182/blood-2007-01-069781
    [61] Tanhapour M, Vaisi-Raygani A, Bahrehmand F, et al. (2016) Association between the cytotoxic t-lymphocyte antigen-4 mutations and the susceptibility to systemic lupus erythematosus; contribution markers of inflammation and oxidative stress. Cell Mol Biol (Noisy-le-grand) 62: 56.
    [62] Ling V, Wu PW, Finnerty HF, et al. (1999) Complete sequence determination of the mouse and human ctla4 gene loci: Cross-species DNA sequence similarity beyond exon borders. Genomics 60: 341-355.
    [63] Yanagawa T, Hidaka Y, Guimaraes V, et al. (1995) Ctla-4 gene polymorphism associated with graves' disease in a caucasian population. J Clin Endocrinol Metab 80: 41-45.
    [64] Vaidya B, Pearce S (2004) The emerging role of the ctla-4 gene in autoimmune endocrinopathies. Eur J Endocrinol 150: 619-626. doi: 10.1530/eje.0.1500619
    [65] Ting WH, Chien MN, Lo FS, et al. (2016) Association of cytotoxic t-lymphocyte-associated protein 4 (ctla4) gene polymorphisms with autoimmune thyroid disease in children and adults: Case-control study. PloS one 11: e0154394. doi: 10.1371/journal.pone.0154394
    [66] Paula AV, Lourdes C, RicardoV GM, et al. (2011) Association of ctla4 gene polymorphism with ophthalmopathy of graves' disease in a spanish population. Int J Endocrinol Metabolism 9: 397-402.
    [67] Du P, Ma X, Wang C (2014) Associations of ctla4 gene polymorphisms with graves' ophthalmopathy: A meta-analysis. Int J Genomics.
    [68] Khalilzadeh O, Amiri HM, Tahvildari M, et al. (2009) Pretibial myxedema is associated with polymorphism in exon 1 of ctla-4 gene in patients with graves' ophthalmopathy. Arch Dermatol Res 301: 719-723. doi: 10.1007/s00403-008-0919-1
    [69] Han S, Zhang S, Zhang W, et al. (2006) Ctla4 polymorphisms and ophthalmopathy in graves' disease patients: Association study and meta-analysis. Hum Immunol 67: 618-626. doi: 10.1016/j.humimm.2006.05.003
    [70] Si X, Zhang X, Tang W, et al. (2012) Association between the ctla-4 +49a/g polymorphism and graves' disease: A meta-analysis. Exp Ther Med 4: 538-544. doi: 10.3892/etm.2012.618
    [71] Devaraju P, Gulati R, Singh B, et al. (2014) The ctla4 +49 a/g (rs231775) polymorphism influences susceptibility to sle in south indian tamils. Tissue Antigens 83: 418-421. doi: 10.1111/tan.12363
    [72] Liu J, Zhang H-X (2013) Ctla-4 polymorphisms and systemic lupus erythematosus: A comprehensive meta-analysis. Genet Test Mol Biomarkers 17: 226-231. doi: 10.1089/gtmb.2012.0302
    [73] Kimkong I, Nakkuntod J, Sae-Ngow S, et al. (2011) Association between ctla-4 polymorphisms and the susceptibility to systemic lupus erythematosus and graves' disease in thai population. Asian Pac J Allergy Immunol 29: 229.
    [74] Chua KH, Puah SM, Chew CH, T et al. (2010) Study of the ctla-4 gene polymorphisms in systemic lupus erythematosus (sle) samples from malaysia. Ann Hum Biol 37: 275-281. doi: 10.3109/03014460903325185
    [75] Ahmed S, Ihara K, Kanemitsu S, et al. (2001) Association of ctla‐4 but not cd28 gene polymorphisms with systemic lupus erythematosus in the japanese population. Rheumatology 40: 662-667.
    [76] Katkam SK, Kumaraswami K, Rupasree Y, T et al. (2016). Association of ctla4 exon-1 polymorphism with the tumor necrosis factor-α in the risk of systemic lupus erythematosus among south indians. Hum Immunol 77: 158-164. doi: 10.1016/j.humimm.2015.11.002
    [77] Barreto M, Santos E, Ferreira R, et al. (2004) Evidence for ctla4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12: 620-626. doi: 10.1038/sj.ejhg.5201214
    [78] Zhai JX, Zou LW, Zhang ZX, et al. (2013) Ctla-4 polymorphisms and systemic lupus erythematosus (sle): A meta-analysis. Mol Biol Rep 40: 5213-5223. doi: 10.1007/s11033-012-2125-7
    [79] Narooie NM, Taji O, Tamandani DMK, et al. (2017) Association of CTLA-4 gene polymorphisms−318c/t and +49a/g and hashimoto's thyroidits in zahedan, iran. Biomed Rep 6: 108-112. doi: 10.3892/br.2016.813
    [80] Liu J, Zhang HX (2014) Ctla-4 gene and the susceptibility of multiple sclerosis: An updated meta-analysis study including 12,916 cases and 15,455 controls. J Neurogenet 28: 153-163. doi: 10.3109/01677063.2014.880703
    [81] Farra C, Awwad J, Fadlallah A, et al. (2012) Genetics of autoimmune thyroid disease in the lebanese population. J Community Genet 3: 259-264. doi: 10.1007/s12687-012-0085-1
    [82] Bicek A, Zaletel K, Gaberscek S, et al. (2009) 49a/g and ct60 polymorphisms of the cytotoxic t-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Hum Immunol 70: 820-824.
    [83] Sameem M, Rani A, Bashir R, et al. (2015) Ctla-4 +49 polymorphism and susceptibility to rheumatoid arthritis in pakistani population. Pakistan J Zool 47: 1731-1737.
    [84] Li G, Shi F, Liu J, et al. (2014) The effect of ctla-4 a49g polymorphism on rheumatoid arthritis risk: A meta-analysis. Diagn Pathol 9: 157. doi: 10.1186/s13000-014-0157-0
    [85] Vaidya B, Pearce S, Charlton S, et al. (2002) An association between the ctla4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 41: 180-183.
    [86] Dai Z, Tian T, Wang M, et al. (2017) Ctla-4 polymorphisms associate with breast cancer susceptibility in asians: A meta-analysis. Peer J 5: e2815.
    [87] Liu P, Xu L, Sun Y, et al. (2014) The association between cytotoxic t lymphocyte-associated antigen-4 and cervical cancer. Tumor Biol 35: 2893-2903.
    [88] Han W-JW (2016) Association of cytotoxic t-lymphocyte antigen-4 polymorphisms with malignant bone tumors risk: A meta-analysis. Asian Pac J Cancer Prev 17: 3785-3791.
    [89] Sáenz LP, Vázquez AF, Romero JM, et al. (2009) Polymorphisms in inflammatory response genes in metastatic renal cancer. Actas Urol Esp 33: 474-481.
    [90] Jaiswal PK, Singh V, Mittal RD (2014) Cytotoxic t lymphocyte antigen 4 (ctla4) gene polymorphism with bladder cancer risk in north indian population. Mol Biol Rep 41: 799-807. doi: 10.1007/s11033-013-2919-2
    [91] Hu L, Liu J, Chen X, et al. (2010) Ctla-4 gene polymorphism +49 a/g contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 71: 888-891. doi: 10.1016/j.humimm.2010.05.023
    [92] Cheng TY, Lin JT, Chen LT, et al. (2006) Association of t-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24: 3483-3489. doi: 10.1200/JCO.2005.05.5434
    [93] Gao X, Zhang S, Qiao X, et al. (2014) Association of cytotoxic t lymphocyte antigen-4 +49a/g polymorphism and cancer risk: An updated meta-analysis. Cancer Biomark 14: 287-294. doi: 10.3233/CBM-140403
    [94] Minhas S, Bhalla S, Shokeen Y, et al. (2014) Lack of any association of the ctla-4 +49 g/a polymorphism with breast cancer risk in a north indian population. Asian Pac J Cancer Prev 15: 2035-2038.
    [95] Qiu H, Tang W, Yin P, et al. (2013) Cytotoxic t-lymphocyte-associated antigen‑4 polymorphisms and susceptibility to cervical cancer: A meta-analysis. Mol Med Rep 8: 1785-1794.
    [96] Khaghanzadeh N, Erfani N, Ghayum MA, et al. (2010) Ctla4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet 196: 171-174. doi: 10.1016/j.cancergencyto.2009.09.001
    [97] Su T-H, Chang T-Y, Lee Y-J, et al. (2007) Ctla-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in taiwanese women. Carcinogenesis 28: 1237-1240. doi: 10.1093/carcin/bgm043
    [98] Bharti V, Mohanti BK, Das SN (2013) Functional genetic variants of ctla-4 and risk of tobacco-related oral carcinoma in high-risk north indian population. Hum Immunol 74: 348-352. doi: 10.1016/j.humimm.2012.12.008
    [99] Touma Z, Hamdan A, Shamseddeen W, et al. (2008) CTLA-4 gene variants are not associated with Behçet's disease or its clinical manifestations. Clin Exp Rheumatol 26: S132.
    [100] Wang L, Li D, Fu Z, et al. (2007) Association of ctla-4 gene polymorphisms with sporadic breast cancer in chinese han population. BMC cancer 7: 173. doi: 10.1186/1471-2407-7-173
    [101] Perez-Garcia A, Brunet S, Berlanga J, et al. (2009) Ctla-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 23: 486-491.
    [102] Erfani N, Haghshenas MR, Hoseini MA, et al. (2012) Strong association of ctla-4 variation (ct60a/g) and ctla-4 haplotypes with predisposition of iranians to head and neck cancer. Iran J Immunol 9: 188.
    [103] Torres B, Aguilar F, Franco E, et al. (2004) Association of the ct60 marker of the ctla4 gene with systemic lupus erythematosus. Arthritis Rheum 50: 2211-2215. doi: 10.1002/art.20347
    [104] Lu L, Wang W, Feng R, et al. (2016) Association between cytotoxic t lymphocyte antigen-4 gene polymorphisms and gastric cancer risk: A meta-analysis of case-control studies. Int J Clin Exp Med 9: 10639-10650.
    [105] Chong KK, Chiang SW, Wong GW, et al. (2008) Association of ctla-4 and il-13 gene polymorphisms with graves' disease and ophthalmopathy in chinese children. Invest Ophthalmol Vis Sci 49: 2409-2415. doi: 10.1167/iovs.07-1433
    [106] Tomoyose T, Komiya I, Takara M, et al. (2002) Cytotoxic t-lymphocyte antigen-4 gene polymorphisms and human t-cell lymphotrophic virus-1 infection: Their associations with hashimoto's thyroiditis in japanese patients. Thyroid 12: 673-677.
    [107] Hudson LL, Rocca K, Song YW, et al. (2002) Ctla-4 gene polymorphisms in systemic lupus erythematosus: A highly significant association with a determinant in the promoter region. Hum Genet 111: 452-455. doi: 10.1007/s00439-002-0807-2
  • This article has been cited by:

    1. Andrei V. Kelarev, Xun Yi, Hui Cui, Leanne Rylands, Herbert F. Jelinek, A survey of state-of-the-art methods for securing medical databases, 2018, 5, 2375-1576, 1, 10.3934/medsci.2018.1.1
    2. Nur Rochmah, Muhammad Faizi, Suhasta Nova, Retno Asih Setyoningrum, Sukmawati Basuki, Anang Endaryanto, CTLA-4 CT-60 A/G and CTLA-4 1822 C/T Gene Polymorphisms in Indonesians with Type 1 Diabetes Mellitus, 2022, Volume 15, 1178-704X, 19, 10.2147/TACG.S359158
    3. Hao-Yun Chang, Chao-Yu Liu, Yen-Li Lo, Shih-Hwa Chiou, Kai-Hsi Lu, Ming-Cheng Lee, Yuan-Hung Wang, Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis, 2023, 86, 1726-4901, 207, 10.1097/JCMA.0000000000000851
    4. Ding-Ping Chen, Su-Wei Chang, Po-Nan Wang, Wei-Tzu Lin, Fang-Ping Hsu, Wei-Ting Wang, Ching-Ping Tseng, The Association Between Single-Nucleotide Polymorphisms of Co-Stimulatory Genes Within Non-HLA Region and the Prognosis of Leukemia Patients With Hematopoietic Stem Cell Transplantation, 2021, 12, 1664-3224, 10.3389/fimmu.2021.730507
    5. Meryem Bouqdayr, Anass Abbad, Hanâ Baba, Asmae Saih, Lahcen Wakrim, Anass Kettani, Computational analysis of structural and functional evaluation of the deleterious missense variants in the human CTLA4 gene, 2023, 0739-1102, 1, 10.1080/07391102.2023.2178509
    6. Ding-Ping Chen, Ying-Hao Wen, Wei-Ting Wang, Wei-Tzu Lin, Exploring the Bio-Functional Effect of Single Nucleotide Polymorphisms in the Promoter Region of the TNFSF4, CD28, and PDCD1 Genes, 2023, 12, 2077-0383, 2157, 10.3390/jcm12062157
    7. Long-Siang Wang, Pang-Chieh Hung, Yu-Kang Chang, Min-Che Tung, Chia-Hung Liu, Yuan-Hung Wang, Association between cytotoxic T-lymphocyte antigen-4 polymorphisms and lung cancer susceptibility: Evidence from a meta-analysis, 2025, 2071-3592, 10.4103/ETMJ.ETMJ-D-24-00045
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6417) PDF downloads(1114) Cited by(7)

Article outline

Figures and Tables

Figures(2)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog